Maux de tête / Migraine
Natural health product licensed in Canada
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| 2,5-Cyclohexadiène-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-décaméthyl-2,6,10,14,18,22,26,30,34,38-tétracontadécaényl]-5,6-diméthoxy-3-méthyl Source : Coenzyme Q10 | 75 mg | Not calculated |
| Tanacetum parthenium Source : Sommité (herbe) Extract : Matériel brut sec Extraction ratio : 20:1 Dry plant equivalent : 80 mg | 4 mg | Not calculated |
Non-medicinal ingredients
Hypromellose, L-Leucine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 2 Capsule | 1 day |
Uses authorised in Canada
Utilisée traditionnellement en phytothérapie/herboristerie pour aider à soulager les maux de tête. Aide à réduire la fréquence des migraines ainsi que les nausées et vomissements qui les accompagnent lorsqu'elle est prise à titre prophylactique/préventif.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Si les symptômes persistent ou s'aggravent, consulter un praticien de soins de santé. Si vous avez des symptômes gastro-intestinaux tels que des nausées, des vomissements, des douleurs abdominales, des difficultés digestives (dyspepsie), des brûlements d'estomac ou de la diarrhée, cesser l'utilisation et consulter un praticien de soins de santé. Si vous souffrez d'asthme ou d'un ulcère gastroduodénal, consulter un praticien de soins de santé avant d'en faire l'usage. Si vous prenez des anticoagulants, des produits renfermant de l'acide acétylsalicylique (AAS) ou d'autres salicylates, ou des médicaments pour la pression sanguine, consulter un praticien de la santé avant d'en faire l'usage. Consulter un praticien de soins de santé si la fréquence des migraines augmente ou si les nausées et les vomissements qui les accompagnent persistent ou s'aggravent.
- Contre-indications
Si vous êtes allergique à l'acide acétylsalicylique (AAS) ou à d'autres salicylates, ne pas utiliser ce produit. Si vous êtes enceinte ou allaitez, ne pas utiliser ce produit.
- Effets indésirables connus
Des douleurs ou des ulcérations buccales et/ou des troubles gastro-intestinaux peuvent se manifester. Ne pas utiliser en cas d'allergie à la famille des Astéracées/Composées/Marguerites. Une hypersensibilité, telle une allergie, peut se manifester. Si tel est le cas, cesser l'utilisation.
Product record
- Licence holder
- Suppléments Aromatik Inc.
- NPN or DIN-HM
- 80091579
- Status
- Active licence
- Licence date
- 2 April 2019
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80091579
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Tanacetum parthenium
Read the warning, when it applies and the studies cited
FEVERFEW - TANACETUM PARTHENIUM
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).
Sources cited by Health Canada (2)
- Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).
Sources cited by Health Canada (1)
- Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.
Contraindications
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.
Do not use if you are pregnant or breastfeeding (EMA 2020).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: All products.
Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).
Sources cited by Health Canada (2)
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).
Sources cited by Health Canada (3)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
- Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Maux de tête / Migraine”, https://compoatlas.com/en/supplements/canada/80091579-maux-de-tete-migraine, updated 2 April 2019.